COLUMBIA LABORATORIES INC
Sector: Drug Delivery
Latest Quote @ Tue May 5 23:46:13 (15 min delayed)
Last Day's Data
Columbia Laboratories, Inc. engages in the development, manufacture, and sale of pharmaceutical products for women's reproductive healthcare and endocrine-related disorders worldwide. Its products and product candidates utilize its Bioadhesive Delivery System, which consists principally of a polymer (polycarbophil) and an active ingredient, and is based upon the principle of bioadhesion, a process by which the polymer adheres to epithelial surfaces or mucosa. This technology delivers a range of compounds, including peptides, across the body's mucosal surfaces to address various therapeutic areas. The company markets Prochieve 8%, a progesterone gel, for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency; and Prochieve 4%, a progesterone gel, for the treatment of secondary amenorrhea. These progesterone gels are sustained release, vaginally delivered, natural progesterone products. Columbia Laboratories also markets Striant, a testosterone buccal system, for the treatment of hypogonadism in men. The company is also investigating the potential utility of Prochieve 8% in the prevention of preterm birth and developing a vaginally-administered lidocaine product to treat dysmenorrhea and pelvic pain. In addition, the company licenses and sells batches of its partnered products to its marketing partners. Columbia Laboratories was incorporated in 1986 and is based in Livingston, New Jersey.